G1T48, an Oral Selective Estrogen Receptor Degrader, and the CDK4/6 Inhibitor Lerociclib Inhibit Tumor Growth in Animal Models of Endocrine-Resistant Breast Cancer

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-020-05575-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2015English

A First in Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for HR+/HER2− Advanced Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

2-Methoxyestradiol Is an Estrogen Receptor Agonist That Supports Tumor Growth in Murine Xenograft Models of Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2005English

Synthetic Cannabinoid Receptor Agonists Inhibit Tumor Growth and Metastasis of Breast Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2009English

Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer

English

Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer

English

Impact of Adding the Multikinase Inhibitor Sorafenib to Endocrine Therapy in Metastatic Estrogen Receptor-Positive Breast Cancer

Future Oncology
MedicineCancer ResearchOncology
2014English

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2016English

Extracellular Alkaline pH Leads to Increased Metastatic Potential of Estrogen Receptor Silenced Endocrine Resistant Breast Cancer Cells

PLoS ONE
Multidisciplinary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy